Iovance Biotherapeutics Inc. [NASDAQ: IOVA] loss -3.21% on the last trading session, reaching $12.38 price per share at the time. The company report on August 4, 2022 that Iovance Biotherapeutics Reports Second Quarter and First Half 2022 Financial Results and Corporate Updates.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
First Biologics License Application (BLA) Submission on Track in August 2022.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today reported second quarter and first half 2022 financial results and corporate updates.
Iovance Biotherapeutics Inc. represents 157.27 million in outstanding shares, while the company has a total market value of $1.83 billion with the latest information. IOVA stock price has been found in the range of $11.95 to $12.665.
If compared to the average trading volume of 5.15M shares, IOVA reached a trading volume of 2228350 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Iovance Biotherapeutics Inc. [IOVA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IOVA shares is $27.38 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IOVA stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wells Fargo have made an estimate for Iovance Biotherapeutics Inc. shares, keeping their opinion on the stock as Equal Weight, with their previous recommendation back on August 18, 2022. While these analysts kept the previous recommendation, Stifel raised their target price from $23 to $25. The new note on the price target was released on January 28, 2022, representing the official price target for Iovance Biotherapeutics Inc. stock.
The Average True Range (ATR) for Iovance Biotherapeutics Inc. is set at 0.78 The Price to Book ratio for the last quarter was 4.11, with the Price to Cash per share for the same quarter was set at 2.88.
Trading performance analysis for IOVA stock
Iovance Biotherapeutics Inc. [IOVA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.56. With this latest performance, IOVA shares dropped by -4.33% in over the last four-week period, additionally sinking by -28.44% over the last 6 months – not to mention a drop of -41.05% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IOVA stock in for the last two-week period is set at 52.37, with the RSI for the last a single of trading hit 50.98, and the three-weeks RSI is set at 52.13 for Iovance Biotherapeutics Inc. [IOVA]. The present Moving Average for the last 50 days of trading for this stock 11.30, while it was recorded at 12.75 for the last single week of trading, and 15.11 for the last 200 days.
Iovance Biotherapeutics Inc. [IOVA]: A deeper dive into fundamental analysis
Iovance Biotherapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.70 and a Current Ratio set at 6.70.
An analysis of insider ownership at Iovance Biotherapeutics Inc. [IOVA]
There are presently around $1,979 million, in the hands of institutional investors. The top three institutional holders of IOVA stocks are: VANGUARD GROUP INC with ownership of 13,363,027, which is approximately 8.276% of the company’s market cap and around 0.10% of the total institutional ownership; PERCEPTIVE ADVISORS LLC, holding 11,826,299 shares of the stock with an approximate value of $146.41 million in IOVA stocks shares; and STATE STREET CORP, currently with $145.72 million in IOVA stock with ownership of nearly 71.943% of the company’s market capitalization.
147 institutional holders increased their position in Iovance Biotherapeutics Inc. [NASDAQ:IOVA] by around 39,658,192 shares. Additionally, 125 investors decreased positions by around 37,350,464 shares, while 21 investors held positions by with 82,825,411 shares. The mentioned changes placed institutional holdings at 159,834,067 shares, according to the latest SEC report filing. IOVA stock had 41 new institutional investments in for a total of 7,077,402 shares, while 52 institutional investors sold positions of 7,755,171 shares during the same period.